<DOC>
	<DOCNO>NCT02647632</DOCNO>
	<brief_summary>The primary objective study estimate , HCV genotype 1 4-infected patient fail prior DAA bitherapy Sofosbuvir , efficacy treatment Grazoprevir/Elbasvir , Sofosbuvir Ribavirin two treatment group compare rate sustain virological response ( SVR ) 12 week 16 24 week treatment . SVR12 define HCV RNA &lt; LLOQ ( either TD [ u ] TND ) .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Grazoprevir/Elbasvir Associated With Sofosbuvir Ribavirin HCV Genotype 1 4-infected Patients Who Failed Direct Acting Antivirals ( DAA ) Bitherapy With Sofosbuvir</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Adult ≥18 year Infection HCV genotype 1 4 , confirm detectable HCV RNA preinclusion Failure prior therapy Sofosbuvir +/ Ribavirin associate Simeprevir Daclatasvir Ledipasvir , document presence NS5A NS3/4A RAVs ( Resistance Associated Variants ) time failure ( presence RAVs least one sample since time failure ) . The proportion patient previously treat Simeprevir limited third patient include . Fibrosis stage Men woman childbearing age heterosexual partner must use adequate contraception 15 day inclusion study 7 month end treatment men 4 month end treatment woman Written inform consent sign patient investigator ( day preinclusion late examination require study ) ( article L112211 Public Health Code ) Patients Health insurance ( Sécurité Sociale Couverture Médicale Universelle ) Child B C cirrhosis ( Child A patient history Child B ) Patients document presence RAVs confer resistance sofosbuvir Positive HBs Antigen Confirmed HIV1 HIV2 infection Pregnant breastfeed woman men whose female partner pregnant Transplant recipients Any evolutive ongoing malignant disease , include hepatocellular carcinoma , specifically screened inclusion History severe rhythm disorder cardiac disease ( coronary artery disease , heart failure , arteriopathy , … ) : opinion cardiologist compulsory ( &lt; 6 month ) Consumption alcohol , investigator 's opinion , obstacle patient 's participation his/her remain study Drug addiction , investigator 's opinion , obstacle patient 's participation his/her remain study . Patients include programme substitution methadone buprenorphine could include . The opinion addictology consultant recommend patient present current drug use drug use past year Patients take part another clinical trial within 30 day prior inclusion Patient guardianship , trusteeship judicial protection Noninclusion biological criterion Hemoglobin &lt; 11 g/dL Platelets &lt; 50 000/mm3 INR &gt; 1.5 unless subject know hemophilia stable anticoagulant regimen affect INR ALT AST &gt; 10xULN Direct bilirubin &gt; 1.5xULN Creatinine clearance &lt; 50 mL/mn ( MDRD formula ) Albumin &lt; 30 g/L HbA1c &gt; 10 % ( diabetic patient ) Criteria relate study drug Contraindication treatment Grazoprevir/Elbasvir , Sofosbuvir Ribavirin include history hypersensitivity one excipients Patients noncompliance history , risk comply study followup timetable Treatment contraindicate associate drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HCV genotype 1 4</keyword>
	<keyword>failure DAA</keyword>
</DOC>